One connected record of American healthcare — provider, payment, prescription, price, safety, ownership, and regulatory data, joined on the keys that link them. Every capability below is a question against that one graph, not a new data project — asked in plain terms and answered from the record, refreshed as the sources refresh.
If you take risk on a population, these five domains are your P&L: the risk you can recapture, the leakage you can close, the practices worth recruiting, and the targets worth acquiring — each answered from the public record.
Not roadmap. Each is backed by a standing query view in the record right now. The full catalog below runs on the same connected graph.
Rank prescribers by what they actually prescribe and bill — not a bought contact list.
Surface the real opinion leaders by prescribing footprint, trial activity, and reach.
See where each payer's coverage stands and which policies gate your product.
Find the sites administering your drug class by J-code and Part B volume.
Tie industry payments to downstream prescribing to see what the spend actually bought.
Track GLP-1 uptake and switching across providers and geographies, quarter over quarter.
Map who administers which regimens, at what volume, by site and region.
Size virtual-care and RPM billing to find the fastest-growing adopters.
Map behavioral-health and SUD treatment by provider, setting, and volume.
Watch originator-to-biosimilar switching by prescriber and period.
Get alerted the moment a provider starts a new drug or bills a new code.
Size the market by procedure volume and the facilities driving it.
Map test ordering and the labs and clinicians behind it.
Track adverse-event trends for any device — yours or a competitor's — in MAUDE.
Trace a recalled device to every facility and provider likely exposed.
Detect emerging safety signals across FAERS and MAUDE as they form.
Estimate off-label use by comparing real prescribing to approved indications.
Reconstruct treatment pathways across procedures, prescriptions, and sites of care.
Build per-product safety scorecards from the adverse-event and recall record.
Assemble utilization and safety evidence in the format payers and FDA expect.
Spot shortage signals from supply, recall, and utilization shifts.
Pick sites and PIs by real patient volume in the target indication.
Build territories on real addressable volume, then set quotas that match.
Rank every account by what it bills and prescribes in your category.
Find the accounts your competitor already pays — and go take them.
Surface high-volume accounts no one is covering yet.
Map who refers to whom so you work the upstream source, not just the site.
Fire outreach the moment an account starts a new code, drug, or volume jump.
Score and enrich your CRM with billing, prescribing, and payment signals.
Segment ABM lists by real economic behavior, not firmographics.
Generate net-new provider and facility leads matched to exactly what you sell.
Rank launch markets by where the target patients and procedures concentrate.
Find the clinicians who adopt new codes first, and start there.
Watch uptake of a new product or code climb, period over period.
Check coverage and fee-schedule status before you launch into a market.
Catch care moving from hospital to ASC to home as it happens.
Monitor early safety signals from the day your product ships.
Track a competitor's launch by their adoption and billing curve.
Validate a target's volume, payer mix, and risk from the public record.
Source fragmented practices that fit a roll-up thesis.
Screen targets as platform or bolt-on by scale and footprint.
Build valuation comps from real volume, ownership, and cost data.
Track who owns what as consolidation moves through a market.
Watch an acquired asset's volume and quality after close.
Screen acquisition targets against a strategic's gaps.
Size the addressable market for a new entrant from real utilization.
Rank every independent PCP-led group in a market, ownership-screened to remove system-, payer-, and academic-owned practices, then run each group’s full clinician panel against the federal + multi-state integrity stack. In four value-based states, 1,010 independent candidates — each cleared against OIG LEIE, 39-state Medicaid exclusions, and the 5-state board feed, with receipts.
Ground equity research in real prescribing, billing, and device volume.
Read utilization trends as alt-data ahead of the print.
Build theses on rising or falling real-world uptake.
Model revenue erosion as biosimilars and generics take share.
Validate a pipeline's real-world traction before the raise.
Design networks and target contracts on real volume and quality.
Flag the billing and payment patterns that signal FWA.
Analyze prescribing against formulary to find leakage and opportunity.
Feed real utilization trends into pricing and underwriting.
Benchmark a plan's spend against market norms.
Compare commercial prices to Medicare-allowed, by code and facility.
The published CY2027 county benchmark plus a pre-registered CY2028 forecast band built off it, calibrated across 12 CMS rate cycles — a bounded, falsifiable rate call that re-prices the day CMS prints the Advance Notice. Every figure carries its basis and as_of date.
Benchmark a system against peers on volume, quality, and cost.
Show a practice exactly where it sits against its peers.
Map SNF, home-health, and hospice referrals and competitors by market.
Benchmark coding and reimbursement to find the leakage.
Model reimbursement across payers and fee schedules.
Pick the next site on real demand and competition.
Forecast capacity strain from volume and workforce signals.
Point it at any county in America and it returns the full Medicare Advantage underwriting input set — eligibles, enrollment, penetration and growth, county benchmarks, payer mix, plan presence across 2.3 million plan×county rows, county risk scores, and PCP supply — in under a second, every figure carrying its CMS source.
Screen providers against OIG exclusions and sanctions in seconds.
Score providers for fraud risk from billing and payment patterns.
Build device and drug liability cases from the safety and exposure record.
Monitor the adverse-event signals that precede mass-tort waves.
Surface the billing anomalies that support qui tam cases.
Physician disciplinary actions from state medical and osteopathic boards — 16,691 actions across five states (AZ, NY, WA, DE, LA), resolved to NPI. Roughly 88% of state-disciplined physicians never appear in the federal integrity screen — the blind spot a public conduct check leaves open.
Map 340B entities and their contract-pharmacy networks.
Flag the dispensing patterns that signal 340B diversion.
Analyze purchasing and supply patterns across facilities.
Clean and enrich any provider file against the federal record.
Find and qualify providers by specialty, volume, and location.
Source and vet experts by real clinical footprint.
Map where specialty access is thin, by geography.
Quantify disparities in access and utilization across populations.
Deliver research-grade, linked datasets for policy and academia.
Support program oversight with linked utilization and ownership data.
Surface grant and RFP opportunities matched to an organization's profile.
License the connected graph as an API or data feed.
Sell practices a dashboard that benchmarks them against their peers.
Turn Concinna into a recurring intelligence media product.
Package linked, structured corpora to train and ground healthcare AI.
Deliver white-label dashboards and embedded analytics to clients.
Validate Medicare Advantage risk scores against the full ICD-10→HCC map (V28 and V24) and real prescribing — the RAF audit ACOs and MA plans run by hand.
Surface the chronic conditions a member's drug regimen implies but the chart hasn't yet coded — the gap between prescribed reality and documented risk.
Name which employer uses which PBM and the disclosed fee, pulled from DOL Form 5500 — OptumRx alone at $1.46B across 295 plans.
Catch employers changing PBMs year over year, with the dollars attached — 25 verified switches, 2022→2023, including Norton Healthcare's $96M move.
Covered lives, premium, carrier, retention, and broker per employer plan — the P&L view a PEO or carve-out prospect can't see about itself.
The 9,826-pharmacy compounding universe and the national PCCA/APC member directories, joined to Part D network reach — the cash-pay supply chain the federal record can't see.
Per-hospital commercial markup × industry payments × Medicare volume × ownership — the cross-source query a price-transparency-only tool structurally cannot run.
Commercial markup vs Medicare vs cost-to-charge vs charity-care spend, per facility — the "what it costs vs what they charge" view, from the hospital's own federal filings.
Join a hospital's commercial pricing posture to the health plan it sponsors for its own employees — pricing aggression on one side of the EIN, benefits economics on the other.
For any drug: which plans cover it, at what tier, behind what prior-auth and step-therapy gates — across 329 formularies, refreshed monthly.
NADAC weekly acquisition cost vs Medicare ASP vs real Part D spend, per drug — the spread every PBM negotiation and carve-out pitch turns on.
Revenue, expenses, and community-benefit posture from IRS filings for 345,000 exempt organizations — the financial reality behind the nonprofit banner.
1.97 million organizations resolved by EIN — the spine that joins hospitals, foundations, plans, and the entities behind them across every other layer.
CMS change-of-ownership filings joined to the ownership and private-equity flags already in the graph — watch control of facilities move.
Every XBRL financial fact for every SEC healthcare filer — the for-profit mirror of the 990 layer: payers, chains, pharma, and the telehealth marketplaces, joined by CIK and EIN.
One pass, five federal conduct authorities: OIG exclusions, SAM debarments (167,580, NPI-keyed), OFAC sanctions (64,179), Commerce trade screening (25,766), and state Medicaid exclusions (39 states, 91,552 records). Clear or flag a target before the wire goes out.
Every inspection, citation, compliance action, and import refusal for a firm — 1.16M events on a single FEI timeline, from first 483 to warning letter to close-out.
Every SEC healthcare filer wired to one entity spine by CIK and EIN — the corporate parent behind the NPIs.
886,072 XBRL facts: what management reports each quarter, laid beside the federal utilization and payment record — self-reported revenue vs the claims arithmetic.
544,000 Form 5500 filing and Schedule A rows resolved to employer EINs and their health carriers — who insures whom, plan size, and the PBM behind the benefit.
Thirteen performance years of MSSP results and the full ACO REACH PUF family — 303,686 provider-roster rows, entity by entity, year by year.
25M FEC individual contributions by employer and occupation, plus federal lobbying filings tied to client names — the influence footprint behind a healthcare entity.
NIH RePORTER grants by organization and investigator joined to HHS award spending — where the federal money goes, and to whom.
1.97M organizations by EIN with IRS 990 financials on 345,000 filers — revenue, expenses, and community-benefit posture behind the nonprofit banner.
Every capability above runs on one connected record. Start with a single market.
Request access